Prognostic role of the stromal tumor-infiltrating lymphocytes (TILs) in women with early ER+/HER2+breast cancer (BC) in whom adjuvant chemotherapy (ChT) was omitted.

被引：0
|
作者：
Horvat, Valentina Jeric
Manevski, Damjan
Gazic, Barbara
Drev, Primoz
Matos, Erika
Ribnikar, Domen
Seruga, Bostjan
机构：
[1] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia
[2] Univ Ljubljana, Inst Biostat & Med Informat, Fac Med, Ljubljana, Slovenia
[3] Inst Oncol Ljubljana, Dept Pathol, Ljubljana, Slovenia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12526
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
    C. Criscitiello
    A. Vingiani
    P. Maisonneuve
    G. Viale
    G. Viale
    G. Curigliano
    Breast Cancer Research and Treatment, 2020, 183 : 347 - 354
  • [2] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [3] Tumor infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Esposito, A.
    Viale, G.
    Curigliano, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER21 breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
    Dieci, M. V.
    Conte, P. F.
    Bisagni, G.
    Brandes, A. A.
    Frassoldati, A.
    Cavanna, L.
    Musolino, A.
    Giotta, F.
    Rimanti, A.
    Garrone, O.
    Bertone, E.
    Cagossi, K.
    Sarti, S.
    Ferro, A.
    Omarini, C.
    Maiorana, A.
    Orvieto, E.
    Sanders, M.
    D'Amico, R.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Tumor-infiltrating lymphocytes (TILs) and 21-gene recurrence score in 1,883 patients with ER+/HER2-breast cancer
    Ahn, Sung Gwe
    Jang, Ji Soo
    Kook, Yoonwon
    Baek, Seung Ho
    Lee, Sae Byul
    Bae, Soong June
    Jeong, Joon
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2-breast cancer (BC).
    Tesch, Megan E.
    Arocho, Yaileen D. Guzman
    Collins, Laura C.
    Heng, Jan
    Zheng, Yue
    Tayob, Nabihah
    Rosenberg, Shoshana M.
    Ruddy, Kathryn Jean
    Tamimi, Rulla
    Schapira, Lidia
    Peppercorn, Jeffrey M.
    Borges, Virginia F.
    Come, Steven E.
    Snow, Craig
    Mittendorf, Elizabeth A.
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Identification of a neoantigen targeted by tumor-infiltrating lymphocytes in a patient with Her2+breast cancer
    Reimann, H.
    Nguyen, A.
    Huebner, H.
    Erber, R.
    Bausenwein, J.
    Van der Meijden, E. D.
    Lux, M. P.
    Jud, S.
    Griffioen, M.
    Rauh, C.
    Sanborn, J. Z.
    Benz, S. C.
    Rabizadeh, S.
    Beckmann, M. W.
    Mackensen, A.
    Ruebner, M.
    Fasching, P. A.
    Kremer, A. N.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] Identification of a neoantigen targeted by tumor-infiltrating lymphocytes in a patient with Her2+breast cancer
    Reimann, H.
    Nguyen, A.
    Huebner, H.
    Erber, R.
    Bausenwein, J.
    Van der Meijden, E. D.
    Lux, M. P.
    Jud, S.
    Griffioen, M.
    Rauh, C.
    Sanborn, J. Z.
    Benz, S. C.
    Rabizadeh, S.
    Beckmann, M. W.
    Mackensen, A.
    Ruebner, M.
    Fasching, P.
    Kremer, A. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 248 - 248
  • [9] Predictive role of stromal tumor infiltrating lymphocytes (TILs) in patients with metastatic HER2-positive breast cancer (BC) treated with trastuzumab
    Yoo, C.
    Yoon, J-A.
    Lee, H. J.
    Ahn, J-H.
    Jung, K. H.
    Gong, G.
    Kim, S. B.
    ANNALS OF ONCOLOGY, 2015, 26 : 18 - 19
  • [10] Predictive role of stromal tumor infiltrating lymphocytes (TILs) in patients with metastatic HER2-positive breast cancer (BC) treated with trastuzumab
    Yoon, J. A.
    Yoo, C.
    Lee, H. J.
    Kim, K-P
    Kim, J.
    Ahn, J-H
    Jung, K. H.
    Gong, G.
    Kim, S-B
    CANCER RESEARCH, 2016, 76
12345